Although several AKT inhibitors have been developed and subjected to clinical trials for NSCLC treatment, their adverse side effects, such as severe hyperglycemia and other potential metabolic abnormalities, hinder their applications (Heavey et al., 2014; Yip, 2015). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.